Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2307
https://www.valueinhealthjournal.com/article/S1098-3015(14)04237-5/fulltext
Title :
Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04237-5&doi=10.1016/j.jval.2014.08.2307
First page :
A640
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1765